Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 PK, safety, and ADH1B genotype impact study of epetraborole in healthy Japanese adults
jRCT2071220004Phase 1Completed
- Sponsor
- AN2 Therapeutics, Inc.
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epetraborole in Mycobacterium avium-intracellulare infection (MAI) (3 cohorts), sponsored by AN2 Therapeutics, Inc. Primary endpoint: Primary: Pharmacokinetics of epetraborole and impact of ADH1B genotype. Started Jun 2022; status: completed.
02
Drugs
epetraborole
03
Conditions
Mycobacterium avium-intracellulare infection (MAI)
Beyond the preview
Go deeper on jRCT2071220004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071220004.